FGI-106 tetrahydrochloride is primarily utilized in research settings for its antiviral properties. It has shown potential in inhibiting the replication of various viruses, making it a candidate for developing treatments against viral infections. Researchers are particularly interested in its efficacy against hemorrhagic fever viruses, such as Ebola and Marburg. Its mechanism of action involves targeting host cell pathways essential for viral replication, reducing the virus's ability to spread. This compound is also studied for its potential to enhance the effectiveness of existing antiviral therapies. Its application is currently limited to laboratory and preclinical studies, with ongoing research to assess its safety and efficacy for potential therapeutic use.